National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Study of Tamoxifen and Raloxifene (STAR) Trial
    Posted: 07/27/2000    Updated: 09/12/2007



Introduction






STAR Background






STAR-At-A Glance






STAR Enrollment Statistics






STAR Images






STAR Publications



Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia

Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E

Past Highlights
Related Pages
Breast Cancer Home Page
NCI's gateway for information about breast cancer.

U.S. Task Force: Chemoprevention of Breast Cancer
The U.S. Preventive Services Task Force has issued two recommendations concerning the use of prescription medicines such as tamoxifen in the prevention of breast cancer.

Estrogen Receptors, Tamoxifen, and Raloxifene
Describes the hormone estrogen and its receptor. Explains the relationship of estrogen and its receptor to breast cancer and the risks and benefits of reducing cancer risk with drugs called antiestrogens and selective estrogen receptor molecules (SERMs).
STAR Images

The National Surgical Adjuvant Breast and Bowel Project (NSABP) maintains a Web site with information about STAR, including a STAR Image Gallery.

Back to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov